Table 2.
First line anti-tuberculosis drug resistance in new and previously treated patients
| Total number of specimens = 2100 |
Previous anti-TB treatment status |
||||||
|---|---|---|---|---|---|---|---|
|
New |
Previously treated |
Total |
|||||
| N | % (95% CI) | N | % (95% CI) | N | % (95% CI) | ||
|
Total DST results |
121 |
5.8 |
98 |
4.7 |
219 |
10.4 |
|
|
I |
Any resistance to H |
32 |
26.4 (19.4–35.4) |
46 |
46.9 (37.1–56.8) |
78 |
35.6 (29.3–42.0) |
| Any resistance to R |
12 |
9.9 (5.8–16.5) |
27 |
27.6 (18.7–36.4) |
39 |
17.8 (12.7–22.9) |
|
| Any resistance to E |
18 |
14.9 (9.6–22.3) |
33 |
33.7 (24.3–43.0) |
51 |
23.3 (17.7–28.9) |
|
| Any resistance to S |
34 |
28.1 (20.9–36.7) |
34 |
34.7 (25.3–44.1) |
68 |
31.1 (24.9–37.2) |
|
|
II |
Resistance to H only |
10 |
8.3 (4.7–15.3) |
14 |
14.3 (7.1–20.9) |
24 |
10.9 (6.8–15.1) |
| Resistance to R only |
0 |
0 (0–0) |
0 |
0 (0–0) |
0 |
0 (0–0) |
|
| Resistance to E only |
0 |
0 (0–0) |
7 |
7.1 (1.9–12.1) |
7 |
3.1 (0.9–5.5) |
|
| Resistance to S only |
15 |
12.4 (8.6–21.4) |
11 |
11.2 (4.8–17.2) |
26 |
11.9 (7.6–16.2) |
|
|
Total mono-resistance |
25 |
20.7 (13.4–27.9) |
32 |
32.6 (23.4–41.9) |
57 |
26.02 (20.2-31.9) |
|
|
III |
H + R |
1 |
0.8 (−0.8–2.8) |
6 |
6.1 (1.3–10.7) |
7 |
3.1 (0.9–5.5) |
| H + R + E |
3 |
2.5 (0.04–6.04) |
7 |
7.1 (1.9–12.1) |
10 |
4.5 (1.8–7.3) |
|
| H + R + S |
3 |
2.5 (0.04–6.04) |
5 |
5.1 (0.7–9.3) |
8 |
3.7 (1.2–6.2) |
|
| H + R + E + S |
5 |
4.1 (1.1–8.9) |
9 |
9.2 (3.3–14.7) |
14 |
6.4 (3.2–9.6) |
|
|
Total MDR |
12 |
9.9 (4.6–15.2) |
27 |
27.6 (18.7–36.4) |
39 |
17.8 (12.7–22.9) |
|
|
IV |
H + E |
4 |
3.3 (0.5–7.5) |
3 |
3.1 (−0.4–6.4) |
7 |
3.1 (0.9–5.5) |
| |
H + S |
5 |
4.1 (1.1–8.9) |
2 |
2.04 (−0.8–4.8) |
7 |
3.1 (0.9–5.5) |
| |
H + E + S |
1 |
0.8 (0.8–2.8) |
3 |
3.1 (−0.4–6.4) |
4 |
1.8 (0.1–3.6) |
| |
R + E |
0 |
0 (0–0) |
0 |
0 (0–0) |
0 |
0 (0–0) |
| |
R + S |
0 |
0 (0–0) |
0 |
0 (0–0) |
0 |
0 (0–0) |
| |
R + E + S |
0 |
0 (0–0) |
0 |
0 (0–0) |
0 |
0 (0–0) |
| |
E + S |
5 |
4.1 (1.1–8.9) |
4 |
4.1 (0.12–7.9) |
9 |
4.1 (1.5–6.7) |
| Total poly-resistance other than MDR | 15 | 12.4 (6.8–18.3) | 12 | 12.2 (5.8–18.7) | 27 | 12.3 (8.0–16.7) | |
CI – confidence interval, DST – drug susceptibility testing, E – ethambutol, H – isoniazid, R – rifampicin, S – streptomycin.